Fig. 3.

Exploratory biomarker analysis by confirmed best overall response to bintrafusp alfa per independent review committee assessment. a Immune phenotype analysis; three patients with immune phenotypes of indeterminate (n = 1) or not annotated (n = 2) are not shown. b Gene expression analysis; three patients with confirmed best overall responses of partial response, stable disease, and progressive disease (n = 1, each) were not included in the RNAseq analysis due to failing QC or lack of RNAseq data. IFNG interferon gamma, NE not evaluable, PD progressive disease, PR partial response, SD stable disease, TGFB1 transforming growth factor beta 1, TPM transcript per million, TWIST1 twist family bHLH transcription factor 1, VIM vimentin